Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.41 |
| ▸ | CTSB | P07858 | 6/20 | 0.41 |
| ▸ | CTSS | P25774 | 6/20 | 0.41 |
| ▸ | CTSK | P43235 | 6/20 | 0.41 |
| ▸ | BCL6 | P41182 | 2/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.40 |
| ▸ | GALR1 | P47211 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | GALR2 | O43603 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6013788 | 0.94 | GALR1 (0.44) | CTSLCTSSCTSKBCL6GALR1 | |
| SCHEMBL4829617 | 0.94 | GALR1 (0.44) | CTSLCTSSCTSKBCL6GALR1 | |
| SCHEMBL6013841 | 0.94 | GALR1 (0.44) | CTSLCTSSCTSKBCL6GALR1 | |
| SCHEMBL4832646 | 0.94 | GALR1 (0.44) | CTSLCTSSCTSKBCL6GALR1 | |
| SCHEMBL4838952 | 0.94 | GALR1 (0.44) | CTSLCTSSCTSKBCL6GALR1 | |
| SCHEMBL4832251 | 0.94 | GALR1 (0.42) | CTSLCTSBCTSSCTSKBCL6 | |
| SCHEMBL5550453 | 0.94 | IDH2 (0.42) | CTSLCTSBCTSSCTSKBCL6 | |
| Hydrochloric Acid SCHEMBL4838895 | 0.94 | GALR1 (0.44) | CTSLCTSSCTSKBCL6GALR1 | |
| SCHEMBL5554791 | 0.92 | IDH2 (0.44) | BCL6EHMT2EHMT1GALR1MAPK1 | |
| SCHEMBL4832502 | 0.91 | GALR1 (0.45) | BCL6EHMT2EHMT1GALR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268134-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-09-11 | — | — | US | claimed |
| US-7112587-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2006-09-26 | — | — | US | claimed |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-26 | — | — | US | claimed |
| WO-2004026844-A9 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS INC (US) | 2004-11-11 | — | — | WO | claimed |
| US-20040209881-A1 | e.g., N-Cycloheptyl-N'(1-ethyl-pyrrolidin-2-ylmethyl)-6-(3-fluoro-4-methoxy-phenoxy)-[1,3,5]triazine-2,4-diamine; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-21 | — | — | US | claimed |
| US-7268134-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7265114-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7112587-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060172984-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-08-03 | — | — | US | disclosed |
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113341-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | CTSL 2784/4885CTSB 2373/4885CTSS 2220/4885 |
| US-20060172984-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | CTSL 2846/4885CTSB 1460/4885CTSS 1860/4885 |
| US-20040209881-A1 | e.g., N-Cycloheptyl-N'(1-ethyl-pyrrolidin-2-ylmethyl)-6-(3-fluoro-4-methoxy-phenoxy)-[1,3,5]triazine-2,4-diamine; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme | ENGASE, LIPG, GPI | CTSL 784/4885CTSB 832/4885CTSS 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.